January 29, 2018
It may be possible to vaccinate against induced NY-ESO-1 expression to produce an antigen-specific immune response in patients with high-risk myelodysplastic syndrome (MDS), according to a […]
January 26, 2018
Venetoclax had promising clinical activity, with a high objective response rate among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with idelalisib, according […]
January 23, 2018
It may be possible to treat patients with relapsed Hodgkin lymphoma (HL) with a new engineered T-cell approach that is less toxic and does not require […]
January 23, 2018
The combination of nivolumab and ipilimumab yielded high response rates and encouraging survival outcomes in a cohort of previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite […]
January 18, 2018
This award signifies MHOA’S laboratory’s commitment to performing quality patient testing and overall laboratory practices. The Laboratory Excellence Award is achieved by those laboratories that are […]
January 1, 2018
Phase 3 results from the ECHELON-1 study, presented at the 59th Annual Meeting & Exposition of the American Society of Hematology, showed superior modified progression-free survival […]
December 19, 2017
Updated analyses are validating the efficacy of copanlisib in the treatment of relapsed or refractory indolent B-cell lymphoma. Investigators reported at the 2017 annual meeting of […]
December 15, 2017
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast […]
December 12, 2017
Clinicians may soon have a valuable new therapeutic option for treating patients with cutaneous T-cell lymphoma (CTCL). Results of a randomized phase III study presented at […]
December 11, 2017
The combination of selinexor and sorafenib appears to be safe with clinical activity and apoptosis induction in patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia […]
December 5, 2017
A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia (AML) cells without harming non-leukemic blood cells
November 13, 2017
Treatment with first-line bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML) compared with treatment with imatinib, according to results of the […]
November 9, 2017
Clinicians now have a new first-line therapy that may significantly improve care for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). On […]
September 13, 2017
When oncologist Dr. Carl June heard the Food and Drug Administration’s decision to bring the first gene therapy to market in the US, he pinched himself, […]
August 18, 2017
The US Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in […]
July 6, 2017
Nivolumab was associated with durable objective response rates (ORRs) in adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation (ASCT), according to […]
June 28, 2017
Clinicians may soon have a new tool to aid patients with refractory acute myeloid leukemia (AML). Researchers at the Perelman School of Medicine at the University […]
June 20, 2016
The American Society of Clinical Oncology’s annual meeting, one of the most important cancer conferences of the year, concluded June 7th. This year’s theme was ‘collective […]
February 5, 2016
The American Society of Hematology (ASH), the premier event for scientific exchange in the field of hematology, recently concluded its annual meeting in Orlando, Florida. Oral […]
July 7, 2015
The annual American Society of Clinical Oncology (ASCO) meeting was held last week in Chicago, bringing together thousands of oncology professionals from around the world to […]
August 1, 2014
[mc_carousel id=”carousel” carousel_images=”2770,2771,2772,2750,2773″ features_images_loop=”1″ lightbox_icon_color=”blue_light” autoplay=”0″ pause_on_hover=”1″ scroll=”1″ effect=”scroll” easing=”swing” duration=”500″ top_margin=”page_margin_top_section” el_position=”first last”] Thank You For Your Interest In Clinical Trials at MHOA Currently Enrolling […]